Pfizer (PFE) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term. Shares of this ...

Pfizer faces weak growth, sector headwinds, and pipeline uncertainty despite cost cuts and a 7% yield, weighing on sentiment.

One relatively safe bet about how Pfizer's lineup will look different five years from now is that the company will be a ...

Pfizer (PFE) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near ...

Pfizer's (NYSE:PFE) stock up by 7.7% over the past three months. However, we decided to study the company's mixed-bag of ...

Pfizer (PFE) is currently under significant scrutiny due to a study linking its product, Depo-Provera, to increased health risks, and an associated Multi-District Litigation could have influenced its ...

Pfizer 's (PFE -0.28%) management team is confident in its 2025 opportunities. *Stock prices used were the afternoon prices of May 20, 2025. The video was published on May 22, 2025.

These might not immediately impact its stock performance, but together with its pipeline goals, they could eventually lead to much stronger returns. Pfizer's decision to license SSGJ-707 doesn't ...

Pfizer (NYSE:PFE) is scheduled to report earnings on Tuesday, April 29, 2025. Looking at PFE’s five-year history, the stock has shown an exact 50-50 split between positive and negative returns ...

So far this year, Pfizer’s stock has declined 13.7% compared with a decrease of 3.6% for the industry. Pfizer Stock Performance Image Source: Zacks Investment Research ...

Looking ahead, Pfizer has maintained its 2025 sales forecast to be in the range of $61 billion to $64 billion, with adjusted earnings projected between $2.80 and $3.00 per share, compared to $63.6 ...